MiMedx Group Inc (MDXG) - Total Liabilities
Based on the latest financial reports, MiMedx Group Inc (MDXG) has total liabilities worth $80.04 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore MiMedx Group Inc operating cash flow efficiency to assess how effectively this company generates cash.
MiMedx Group Inc - Total Liabilities Trend (2006–2024)
This chart illustrates how MiMedx Group Inc's total liabilities have evolved over time, based on quarterly financial data. Check MDXG asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
MiMedx Group Inc Competitors by Total Liabilities
The table below lists competitors of MiMedx Group Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Merida Industry Co Ltd
TW:9914
|
Taiwan | NT$16.65 Billion |
|
PAM Mineral Tbk PT
JK:NICL
|
Indonesia | Rp138.61 Billion |
|
Flushing Financial Corporation
NASDAQ:FFIC
|
USA | $7.99 Billion |
|
AB S.A.
WAR:ABE
|
Poland | zł2.69 Billion |
|
Sage Therapeutics Inc
NASDAQ:SAGE
|
USA | $54.19 Million |
|
Huaren Pharmaceutical Co Ltd
SHE:300110
|
China | CN¥1.97 Billion |
|
Hangzhou Seck Intelligent Tech Co
SHE:300897
|
China | CN¥257.52 Million |
|
C.E. Info Systems Limited
NSE:MAPMYINDIA
|
India | Rs1.41 Billion |
Liability Composition Analysis (2006–2024)
This chart breaks down MiMedx Group Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see MDXG market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.41 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how MiMedx Group Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for MiMedx Group Inc (2006–2024)
The table below shows the annual total liabilities of MiMedx Group Inc from 2006 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $70.81 Million | -26.49% |
| 2023-12-31 | $96.33 Million | -0.61% |
| 2022-12-31 | $96.92 Million | +1.65% |
| 2021-12-31 | $95.35 Million | -13.80% |
| 2020-12-31 | $110.61 Million | +51.13% |
| 2019-12-31 | $73.19 Million | 0.00% |
| 2018-12-31 | $73.19 Million | +54.22% |
| 2017-12-31 | $47.46 Million | -21.25% |
| 2016-12-31 | $60.26 Million | +115.80% |
| 2015-12-31 | $27.93 Million | +40.12% |
| 2014-12-31 | $19.93 Million | +79.13% |
| 2013-12-31 | $11.13 Million | -26.68% |
| 2012-12-31 | $15.18 Million | -0.16% |
| 2011-12-31 | $15.20 Million | +1114.30% |
| 2010-12-31 | $1.25 Million | -65.42% |
| 2009-12-31 | $3.62 Million | +281.69% |
| 2008-12-31 | $948.48K | +2550.71% |
| 2007-12-31 | $35.78K | +237.88% |
| 2006-12-31 | $10.59K | -- |
About MiMedx Group Inc
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines,… Read more